Showing 1811-1820 of 4063 results for "".
- Okogen Announces Interim Analysis Results From RUBY Phase 2 Trial for Acute Adenoviral Conjunctivitis Drug Candidatehttps://modernod.com/news/okogen-announces-interim-analysis-results-from-ruby-phase-2-trial-for-acute-adenoviral-conjunctivitis-drug-candidate/2479140/Okogen announced the interim analysis results from RUBY, the company’s phase 2, double-masked, placebo-controlled clinical trial evaluating the safety and efficacy of OKG-0301 in patients with acute adenoviral conjunctivitis. In 58 patients diagnosed with acute adenoviral conjunctivitis, OKG-0301
- Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302 Anti-VEGF for Wet AMDhttps://modernod.com/news/innovent-announces-first-patient-dosed-in-the-phase-2-clinical-trial-of-ibi302-anti-vegf-for-wet-amd/2479137/Innovent Biologics announces that the first patient has been successfully dosed in a phase 2 clinical trial for IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein. This study is a randomized, double-blind, multicenter, active-cont
- ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at ARVO 2021https://modernod.com/news/proqr-announces-virtual-presentation-of-phase-1-2-sepofarsen-extension-trial-data-at-arvo-2021/2479108/ProQR Therapeutics announced a virtual oral presentation of data from the company’s phase 1/2 InSight extension trial of sepofarsen and live Q&A session at the Association for Research in Vision and Ophthalmology (ARVO) held May 1-7, 2021. This is an encore presentation of the In
- Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of Investigational Glaucoma Drug QLS-101https://modernod.com/news/qlaris-bio-enrolls-first-patient-in-phase-1-2-studies-of-investigational-glaucoma-drug-qls-101/2479081/Qlaris Bio announced the enrollment of the first patient in the phase 1/2 clinical program for QLS-101, an investigational therapy designed to lower IOP by reducing episcleral venous pressure (EVP) in individuals with glaucoma. QLS-101 is a novel adenosine triphosphate (ATP)-sensitive pota
- Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathyhttps://modernod.com/news/ocuphire-initiates-zeta-1-phase-2-clinical-trial-investigating-apx3330-in-diabetic-retinopathy/2479060/Ocuphire Pharma announced that it has screened the first patient in ZETA-1, a phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR). Effects on diabetic macular edema will be explored as a secondary outcome. A number o
- Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpointhttps://modernod.com/news/ocuphire-announces-mira-2-phase-3-registration-trial-for-the-reversal-of-mydriasis-meets-primary-endpoint/2478967/Ocuphire Pharma announced positive topline results in the MIRA-2 phase 3 registration trial investigating its product candidate Nyxol for reversal of pharmacologically induced mydriasis (dilation of pupil for eye exams). Nyxol is a proprietary, preservative-free, stable, investigational eye drop
- Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of Investigational Treatment for MGDhttps://modernod.com/news/azura-ophthalmics-announces-positive-topline-results-from-phase-2-program-of-the-companys-investigational-treatment-for-mgd/2478934/Azura Ophthalmics announced topline results from a phase 2 program evaluating the company’s investigational therapy for the treatment of Meibomian gland dysfunction (MGD). AZR-MD-001 met its primary endpoints showing improvements in signs and symptoms of MGD, reaching statistical significance com
- Accure Therapeutics Enrolls First Patient in Phase 2 Clinical Trial on Acute Optic Neuritishttps://modernod.com/news/accure-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-on-acute-optic-neuritis/2478923/Accure Therapeutics announced it has enrolled the first patient in its ACUITY phase 2 clinical trial in patients with acute optic neuritis (AON). A total of 36 patients will be enrolled in two randomized parallel groups. They will be followed for 6 months to measure and assess safety and prelimin
- Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-initiates-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-presbyopia/2478887/Ocuphire Pharma announced that it has enrolled the first patients in a phase 2 proof of concept trial, titled VEGA-1, to evaluate a combination kit of Nyxol and low-dose pilocarpine in presbyopia. Over 12 sites representing a majority of the planned clinical sites are activated and recruiting pat
- Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophyhttps://modernod.com/news/trefoil-therapeutics-begins-second-phase-2-storm-clinical-trial-with-regenerative-treatment-for-fuchs-endothelial-corneal-dystrophy/2478856/Trefoil Therapeutics announced it has begun a phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a regenerative treatment for patients with Fuchs Endothelial Corneal Dystrophy (FECD). The “STORM” study, the second clinical trial o